Hogan Lovells advises PerkinElmer, Inc. on the acquisition of SIRION BIOTECH GmbH

Press releases | 23 June 2021

Led by Head of the Munich Corporate Group Lutz Angerer, international law firm Hogan Lovells has advised listed US company PerkinElmer, Inc. on the acquisition of SIRION BIOTECH GmbH, a leading global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Headquartered in Munich, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty five diseases and conditions.

The addition of SIRION's offerings will complement PerkinElmer's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies. Moreover, the acquisition will further broaden PerkinElmer's existing cell and gene research solutions featuring industry-leading high content, in vivo, and cell painting screening technologies; innovative immunoassays; cell plate readers; and advanced automation, microfluidics and informatics and analytical platforms.

Partner Lutz Angerer has advised PerkinElmer since 2004 on various M&A transactions, including the acquisition of chemagen Biopolymer-Technologie AG, Evotec Technologies GmbH, Elcos AG and EUROIMMUN Medizinische Labordiagnostika AG as well as the disposal of its Medical Imaging Business. Commenting, he said:

"Our life sciences industry and cross-border deal expertise helped us to push this transaction over the finishing line within a short period of time."

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, they deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. They strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Their dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.

Hogan Lovells for PerkinElmer

Dr. Lutz Angerer (Lead Partner, M&A, Munich), Guido Brockhausen (Lead Counsel, M&A, Dusseldorf), Andreas Thun (Counsel), Thomas Weber (Counsel), Dr. Thomas Richter (Senior Associate), Stephanie Brüggemann (Associate) (all M&A, Munich);

Dr. Falk Loose (Counsel, Tax, Munich);

Dr. Jörg Schickert (Partner), Dr. Benjamin Goehl (Associate) (both Commercial Regulatory, Munich);

Dr. Falk Schöning (Partner), Stefan Kirwitzke (Associate) (both Antitrust and Competition, Brussels);

Dr. Tim Joppich (Partner, Employment, Dusseldorf).